Aldeyra Resubmits Drug Application for Dry Eye Treatment to FDA, Receives FDA Approval for Reproxalap Treatment

Aldeyra Therapeutics has resubmitted its new drug application for reproxalap, a treatment for dry eye disease, to the FDA. The application includes new clinical data from a successful trial that met its primary endpoint. Analysts forecast an average target price of $8.67, implying an 186.98% upside from the current price of $3.02. The consensus recommendation is "Buy" with an average brokerage recommendation of 1.5.